Anti-cytokine therapies for psoriasis (Q37837129)

24 August 2017

1 reference

title

Anti-cytokine therapies for psoriasis (English)

1 reference

24 August 2017

Kristine E Nograles

1

1 reference

24 August 2017

James G Krueger

series ordinal

2

1 reference

24 August 2017

language of work or name

English

0 references

publication date

4 February 2011

1 reference

Experimental Cell Research

24 August 2017

published in

1 reference

24 August 2017

volume

317

1 reference

24 August 2017

issue

9

1 reference

24 August 2017

page(s)

1293-1300

1 reference

Psoriasis--epidemiology and clinical spectrum

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.01.024

Pathogenesis and therapy of psoriasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.01.024

Psoriasis: evolution of pathogenic concepts and new therapies through phases of translational research

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.01.024

Cyclosporine improves psoriasis in a double-blind study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.01.024

Tacrolimus (FK 506)--a new therapeutic agent for severe recalcitrant psoriasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.01.024

Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.01.024

Plasmacytoid predendritic cells initiate psoriasis through interferon-alpha production.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.01.024

Resident and "inflammatory" dendritic cells in human skin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.01.024

Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.01.024

Critical role for STAT4 activation by type 1 interferons in the interferon-gamma response to viral infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.01.024

Type I interferon as a powerful adjuvant for monocyte-derived dendritic cell development and activity in vitro and in Hu-PBL-SCID mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.01.024

A randomized, double-blind, placebo-controlled, phase I study of MEDI-545, an anti-interferon-alfa monoclonal antibody, in subjects with chronic psoriasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.01.024

Psoriasis is characterized by accumulation of immunostimulatory and Th1/Th17 cell-polarizing myeloid dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.01.024

Identification of TNF-related apoptosis-inducing ligand and other molecules that distinguish inflammatory from resident dendritic cells in patients with psoriasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.01.024

Increase in TNF-alpha and inducible nitric oxide synthase-expressing dendritic cells in psoriasis and reduction with efalizumab (anti-CD11a)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.01.024

Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.01.024

Natural killer cell stimulatory factor (interleukin 12 [IL-12]) induces T helper type 1 (Th1)-specific immune responses and inhibits the development of IL-4-producing Th cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.01.024

Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.01.024

Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.01.024

Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.01.024

Polymorphisms of the IL12B and IL23R genes are associated with psoriasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.01.024

Genome-wide scan reveals association of psoriasis with IL-23 and NF-kappaB pathways

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.01.024

Psoriasis Vulgaris Lesions Contain Discrete Populations of Th1 and Th17 T Cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.01.024

IL-17A enhances vitamin D3-induced expression of cathelicidin antimicrobial peptide in human keratinocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.01.024

Self-RNA-antimicrobial peptide complexes activate human dendritic cells through TLR7 and TLR8.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.01.024

Identification of common transcriptional regulatory elements in interleukin-17 target genes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.01.024

Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.01.024

IL-22-producing "T22" T cells account for upregulated IL-22 in atopic dermatitis despite reduced IL-17-producing TH17 T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.01.024

Identification of a human helper T cell population that has abundant production of interleukin 22 and is distinct from T(H)-17, T(H)1 and T(H)2 cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.01.024

Production of interleukin 22 but not interleukin 17 by a subset of human skin-homing memory T cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.01.024

Activation of the aryl hydrocarbon receptor reveals distinct requirements for IL-22 and IL-17 production by human T helper cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.01.024

Identification and quantitation of interferon-gamma producing T cells in psoriatic lesions: localization to both CD4+ and CD8+ subsets

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.01.024

The majority of epidermal T cells in Psoriasis vulgaris lesions can produce type 1 cytokines, interferon-gamma, interleukin-2, and tumor necrosis factor-alpha, defining TC1 (cytotoxic T lymphocyte) and TH1 effector populations: a type 1 differentiat

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.01.024

Interleukin-11 therapy selectively downregulates type I cytokine proinflammatory pathways in psoriasis lesions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.01.024

Response of psoriasis to interleukin-10 is associated with suppression of cutaneous type 1 inflammation, downregulation of the epidermal interleukin-8/CXCR2 pathway and normalization of keratinocyte maturation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.01.024

Interleukin-4 therapy of psoriasis induces Th2 responses and improves human autoimmune disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.01.024

Blockade of T lymphocyte costimulation with cytotoxic T lymphocyte-associated antigen 4-immunoglobulin (CTLA4Ig) reverses the cellular pathology of psoriatic plaques, including the activation of keratinocytes, dendritic cells, and endothelial cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.01.024

CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.01.024

Alefacept (anti-CD2) causes a selective reduction in circulating effector memory T cells (Tem) and relative preservation of central memory T cells (Tcm) in psoriasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.01.024

A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.01.024

Alefacept reduces infiltrating T cells, activated dendritic cells, and inflammatory genes in psoriasis vulgaris

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.01.024

Alefacept therapy produces remission for patients with chronic plaque psoriasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.01.024

Efalizumab (anti-CD11a)-induced increase in peripheral blood leukocytes in psoriasis patients is preferentially mediated by altered trafficking of memory CD8+ T cells into lesional skin.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.01.024

Blockade of CD11a by Efalizumab in Psoriasis Patients Induces a Unique State of T-Cell Hyporesponsiveness

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.01.024

Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.01.024

Psoriasis as a model for T-cell-mediated disease: immunobiologic and clinical effects of treatment with multiple doses of efalizumab, an anti-CD11a antibody.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.01.024

Relapse, rebound, and psoriasis adverse events: an advisory group report.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.01.024

Integrative responses to IL-17 and TNF-α in human keratinocytes account for key inflammatory pathogenic circuits in psoriasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.01.024

Treatment with anti-tumor necrosis factor alpha (TNF-alpha) monoclonal antibody dramatically decreases the clinical activity of psoriasis lesions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.01.024

Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.01.024

A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.01.024

Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.01.024

Lymphoma in patients treated with anti-TNF: results of the 3-year prospective French RATIO registry

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.01.024

Effective treatment of psoriasis with etanercept is linked to suppression of IL-17 signaling, not immediate response TNF genes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.01.024

TNFalpha blockade in human diseases: mechanisms and future directions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.01.024

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.01.024

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.01.024

Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.01.024

Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomized, placebo-controlled, phase 2 trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.01.024

Th22 cells represent a distinct human T cell subset involved in epidermal immunity and remodeling

7 January 2021

1 reference

31 May 2024

https://opencitations.net/index/api/v1/citations/10.1172/JCI40202

Identifiers

DOI

10.1016/J.YEXCR.2011.01.024

1 reference

24 August 2017

1 reference